The group's principal activities are to develop and sale of medical technology. The group develops and markets portable electrocardiograph (ecg) monitor. Other activity of the group is to research and develop a device to measure hematocrit technology. The hematocrit is the percentage of red blood cells in a given volume of blood. The group entered into a development, licensing and manufacturing agreement with chi lin pursuant to which inmedica granted chi lin a worldwide license to develop and manufacture products based on the hematocrit technology.
